APLLTD vs GLENMARK: Stock Comparison
GLENMARK PHARMACEUTICALS is the larger company by market capitalisation. ALEMBIC PHARMA shows a lower P/E, a higher dividend yield and a higher net margin, while GLENMARK PHARMACEUTICALS shows a higher ROE, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
APLLTD leads 5; GLENMARK leads 8 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | APLLTD | GLENMARK |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | APLLTD | GLENMARK |
|---|---|---|
| Live Price | ₹808.2 | ₹2,437.2 |
| Day Change | 0.57% | -0.89% |
| Volume | 1.74 L | 4.13 L |
| 52-Week High | ₹998 | ₹2,537.6 |
| 52-Week Low | ₹635.8 | ₹1,792.6 |
| Distance from 52W High | -19.02% | -3.96% |
Valuation
| Metric | APLLTD | GLENMARK |
|---|---|---|
| Market Cap | ₹15,837 Cr | ₹68,490 Cr |
| P/E Ratio | 23.35x | 46.23x |
| P/B Ratio | 2.85x | 6.58x |
| EPS | ₹10.02 | ₹26.07 |
| Book Value | ₹288.41 | ₹372.49 |
| Dividend Yield | 1.49% | 0.21% |
Growth
| Metric | APLLTD | GLENMARK |
|---|---|---|
| Revenue Growth (TTM YoY) | 4.4% | 14.3% |
| EPS Growth (TTM YoY) | 29.2% | 6,575% |
| Qtr Sales Growth | -13.1% | -39.41% |
| Qtr Profit Growth | 14.27% | 52.36% |
Profitability & Leverage
| Metric | APLLTD | GLENMARK |
|---|---|---|
| ROE | 11.4% | 12.96% |
| ROCE | 10.99% | 18.25% |
| Net Margin | 8.98% | 8.15% |
| Operating Margin | 11.13% | 12.92% |
| Debt to Equity | 0.2x | 0x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | APLLTD | GLENMARK |
|---|---|---|
| Promoter Holding | 69.36%▲ 0.13 pp | 46.65% |
| FII Holding | 4.18%▼ 0.07 pp | 20.89%▲ 0.55 pp |
| DII Holding | 15.94%▼ 0.24 pp | 18.6%▼ 0.69 pp |
| Public Holding | 10.01%▲ 0.18 pp | 13.81%▲ 0.13 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ALEMBIC PHARMA and GLENMARK PHARMACEUTICALS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.